vs
COMSTOCK RESOURCES INC（CRK）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
COMSTOCK RESOURCES INC的季度营收约是Revvity的1.0倍（$787.3M vs $772.1M），COMSTOCK RESOURCES INC净利率更高（35.7% vs 12.7%，领先22.9%），COMSTOCK RESOURCES INC同比增速更快（114.3% vs 5.9%），Revvity自由现金流更多（$161.8M vs $-141.2M），过去两年COMSTOCK RESOURCES INC的营收复合增速更高（53.1% vs 9.0%）
Comstock Resources Inc.是一家独立能源企业，主要从事天然气、原油及天然气凝液的勘探、开发、生产与销售业务，核心运营资产位于美国得州和路易斯安那州的页岩产区，服务北美能源市场。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
CRK vs RVTY — 直观对比
营收规模更大
CRK
是对方的1.0倍
$772.1M
营收增速更快
CRK
高出108.5%
5.9%
净利率更高
CRK
高出22.9%
12.7%
自由现金流更多
RVTY
多$303.0M
$-141.2M
两年增速更快
CRK
近两年复合增速
9.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $787.3M | $772.1M |
| 净利润 | $280.9M | $98.4M |
| 毛利率 | — | — |
| 营业利润率 | 48.3% | 14.5% |
| 净利率 | 35.7% | 12.7% |
| 营收同比 | 114.3% | 5.9% |
| 净利润同比 | 583.3% | 3.9% |
| 每股收益（稀释后） | $0.99 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CRKRVTY
| Q4 25 | $787.3M | $772.1M | ||
| Q3 25 | $449.9M | $698.9M | ||
| Q2 25 | $470.3M | $720.3M | ||
| Q1 25 | $512.9M | $664.8M | ||
| Q4 24 | $367.4M | $729.4M | ||
| Q3 24 | $304.5M | $684.0M | ||
| Q2 24 | $246.8M | $691.7M | ||
| Q1 24 | $335.8M | $649.9M |
净利润CRKRVTY
| Q4 25 | $280.9M | $98.4M | ||
| Q3 25 | $111.1M | $46.7M | ||
| Q2 25 | $124.8M | $53.9M | ||
| Q1 25 | $-121.3M | $42.2M | ||
| Q4 24 | $-58.1M | $94.6M | ||
| Q3 24 | $-28.9M | $94.4M | ||
| Q2 24 | $-126.3M | $55.4M | ||
| Q1 24 | $-16.3M | $26.0M |
毛利率CRKRVTY
| Q4 25 | — | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | — | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 55.7% | ||
| Q1 24 | — | 54.6% |
营业利润率CRKRVTY
| Q4 25 | 48.3% | 14.5% | ||
| Q3 25 | 11.2% | 11.7% | ||
| Q2 25 | 19.0% | 12.6% | ||
| Q1 25 | 24.6% | 10.9% | ||
| Q4 24 | -0.5% | 16.3% | ||
| Q3 24 | -20.1% | 14.3% | ||
| Q2 24 | -37.5% | 12.4% | ||
| Q1 24 | -3.8% | 6.8% |
净利率CRKRVTY
| Q4 25 | 35.7% | 12.7% | ||
| Q3 25 | 24.7% | 6.7% | ||
| Q2 25 | 26.5% | 7.5% | ||
| Q1 25 | -23.6% | 6.4% | ||
| Q4 24 | -15.8% | 13.0% | ||
| Q3 24 | -9.5% | 13.8% | ||
| Q2 24 | -51.2% | 8.0% | ||
| Q1 24 | -4.9% | 4.0% |
每股收益（稀释后）CRKRVTY
| Q4 25 | $0.99 | $0.86 | ||
| Q3 25 | $0.40 | $0.40 | ||
| Q2 25 | $0.44 | $0.46 | ||
| Q1 25 | $-0.40 | $0.35 | ||
| Q4 24 | $-0.19 | $0.77 | ||
| Q3 24 | $-0.09 | $0.77 | ||
| Q2 24 | $-0.43 | $0.45 | ||
| Q1 24 | $-0.05 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $23.9M | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.6B | $7.3B |
| 总资产 | $7.0B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CRKRVTY
| Q4 25 | $23.9M | $919.9M | ||
| Q3 25 | $19.2M | $931.4M | ||
| Q2 25 | $25.9M | $991.8M | ||
| Q1 25 | $32.9M | $1.1B | ||
| Q4 24 | $6.8M | $1.2B | ||
| Q3 24 | $13.8M | $1.2B | ||
| Q2 24 | $19.3M | $2.0B | ||
| Q1 24 | $6.4M | $1.7B |
股东权益CRKRVTY
| Q4 25 | $2.6B | $7.3B | ||
| Q3 25 | $2.4B | $7.4B | ||
| Q2 25 | $2.2B | $7.6B | ||
| Q1 25 | $2.1B | $7.6B | ||
| Q4 24 | $2.2B | $7.7B | ||
| Q3 24 | $2.3B | $7.9B | ||
| Q2 24 | $2.3B | $7.9B | ||
| Q1 24 | $2.4B | $7.8B |
总资产CRKRVTY
| Q4 25 | $7.0B | $12.2B | ||
| Q3 25 | $6.8B | $12.1B | ||
| Q2 25 | $6.7B | $12.4B | ||
| Q1 25 | $6.6B | $12.4B | ||
| Q4 24 | $6.4B | $12.4B | ||
| Q3 24 | $6.3B | $12.8B | ||
| Q2 24 | $6.3B | $13.4B | ||
| Q1 24 | $6.3B | $13.4B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $224.2M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $-141.2M | $161.8M |
| 自由现金流率自由现金流/营收 | -17.9% | 21.0% |
| 资本支出强度资本支出/营收 | 46.4% | 2.6% |
| 现金转化率经营现金流/净利润 | 0.80× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $-449.7M | $509.4M |
8季度趋势，按日历期对齐
经营现金流CRKRVTY
| Q4 25 | $224.2M | $182.0M | ||
| Q3 25 | $153.1M | $138.5M | ||
| Q2 25 | $347.6M | $134.3M | ||
| Q1 25 | $174.7M | $128.2M | ||
| Q4 24 | $267.1M | $174.2M | ||
| Q3 24 | $98.2M | $147.9M | ||
| Q2 24 | $83.6M | $158.6M | ||
| Q1 24 | $171.5M | $147.6M |
自由现金流CRKRVTY
| Q4 25 | $-141.2M | $161.8M | ||
| Q3 25 | $-188.4M | $120.0M | ||
| Q2 25 | $3.2M | $115.5M | ||
| Q1 25 | $-123.2M | $112.2M | ||
| Q4 24 | $-12.9M | $149.8M | ||
| Q3 24 | $-131.1M | $125.6M | ||
| Q2 24 | $-153.2M | $136.6M | ||
| Q1 24 | $-179.9M | $129.7M |
自由现金流率CRKRVTY
| Q4 25 | -17.9% | 21.0% | ||
| Q3 25 | -41.9% | 17.2% | ||
| Q2 25 | 0.7% | 16.0% | ||
| Q1 25 | -24.0% | 16.9% | ||
| Q4 24 | -3.5% | 20.5% | ||
| Q3 24 | -43.1% | 18.4% | ||
| Q2 24 | -62.1% | 19.7% | ||
| Q1 24 | -53.6% | 20.0% |
资本支出强度CRKRVTY
| Q4 25 | 46.4% | 2.6% | ||
| Q3 25 | 75.9% | 2.6% | ||
| Q2 25 | 73.2% | 2.6% | ||
| Q1 25 | 58.1% | 2.4% | ||
| Q4 24 | 76.2% | 3.4% | ||
| Q3 24 | 75.3% | 3.3% | ||
| Q2 24 | 95.9% | 3.2% | ||
| Q1 24 | 104.7% | 2.7% |
现金转化率CRKRVTY
| Q4 25 | 0.80× | 1.85× | ||
| Q3 25 | 1.38× | 2.97× | ||
| Q2 25 | 2.78× | 2.49× | ||
| Q1 25 | — | 3.03× | ||
| Q4 24 | — | 1.84× | ||
| Q3 24 | — | 1.57× | ||
| Q2 24 | — | 2.87× | ||
| Q1 24 | — | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CRK
| Other | $420.7M | 53% |
| Natural Gas And Oil Sales | $366.6M | 47% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
